TrialSignal
Clinical trial intelligence report
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01976728
Status
COMPLETED
Phase
PHASE3
Sponsor
Ferring Pharmaceuticals
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the efficacy of three doses of Gonadorelin acetate administered via the OmniPod pump for ovulation induction in women with primary amenorrhea due to hypogonadotropic hypogonadism. The study was sponsored by Ferring Pharmaceuticals and completed in February 2018.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01976728
Indication
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Modality
small molecule
Target
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Intervention
Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.